Related references
Note: Only part of the references are listed.Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir
Jurrien G. P. Reijnders et al.
JOURNAL OF HEPATOLOGY (2011)
Prediction of Sustained Response to Peginterferon Alfa-2b for Hepatitis B e Antigen Positive Chronic Hepatitis B Using On-Treatment Hepatitis B Surface Antigen Decline
Milan J. Sonneveld et al.
HEPATOLOGY (2010)
Serum Hepatitis B Surface Antigen and Hepatitis B e Antigen Titers: Disease Phase Influences Correlation with Viral Load and Intrahepatic Hepatitis B Virus Markers
Alexander J. V. Thompson et al.
HEPATOLOGY (2010)
Risk assessment for the development of hepatocellular carcinoma: According to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease
Jong Ryul Eun et al.
JOURNAL OF HEPATOLOGY (2010)
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B
R. G. Gish et al.
JOURNAL OF VIRAL HEPATITIS (2010)
Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B
Vincent Wai-Sun Wong et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
Fabien Zoulim et al.
GASTROENTEROLOGY (2009)
Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa
Erik H. C. J. Buster et al.
GASTROENTEROLOGY (2009)
Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a
Patrick Marcellin et al.
GASTROENTEROLOGY (2009)
Hepatitis B Virus Surface Antigen Levels: A Guide to Sustained Response to peginterferon alfa-2a in HBeAg-Negative Chronic Hepatitis B
Maurizia Rossana Brunetto et al.
HEPATOLOGY (2009)
The Natural History of Chronic Hepatitis B Virus Infection
Brian J. McMahon
HEPATOLOGY (2009)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Patrick Marcellin et al.
JOURNAL OF HEPATOLOGY (2009)
Clearance of Serum HBsAg and Anti-HBs Seroconversion Following Antiviral Therapy for Chronic Hepatitis B
Olivier Borgniet et al.
JOURNAL OF MEDICAL VIROLOGY (2009)
A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients
R. Idilman et al.
JOURNAL OF VIRAL HEPATITIS (2009)
Natural history of chronic hepatitis B virus infection and long-term outcome under treatment
Yun-Fan Liaw
LIVER INTERNATIONAL (2009)
Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response
Man-Fung Yuen et al.
HEPATOLOGY (2007)
Prevention by Lamivudine of Hepatocellular Carcinoma in Patients Infected with Hepatitis B Virus
Heon Ju Lee et al.
GUT AND LIVER (2007)
Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response
Henry Lik-Yuen Chan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
The natural history and evaluation of standard treatment of chronic hepatitis B: A critical treatment criteria and end points
Ching-Lung Lai et al.
ANNALS OF INTERNAL MEDICINE (2007)
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
UH Iloeje et al.
GASTROENTEROLOGY (2006)
Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B:: HBsAg loss is associated with HBV genotype
HJ Flink et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
CJ Chen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients
A Matsumoto et al.
HEPATOLOGY RESEARCH (2005)
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy
JJY Sung et al.
GASTROENTEROLOGY (2005)
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
D Lavanchy
JOURNAL OF VIRAL HEPATITIS (2004)
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
P Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients
AM Bozdayi et al.
ARCHIVES OF VIROLOGY (2004)
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy
B Werle-Lapostolle et al.
GASTROENTEROLOGY (2004)
Lamivudine for patients with chronic hepatitis B and advanced liver disease
YF Liaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy
P Lampertico et al.
HEPATOLOGY (2003)
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B
CL Lai et al.
CLINICAL INFECTIOUS DISEASES (2003)
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
ASF Lok et al.
GASTROENTEROLOGY (2003)
Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus
BJ McMahon et al.
ANNALS OF INTERNAL MEDICINE (2001)
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy
MF Yuen et al.
HEPATOLOGY (2001)